Leveraging next gen technologies beyond conventional biomarker drug discovery
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 20-23 October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Why our Virtual event is essential viewing:
- A speaker faculty even better than before: You’ll learn from 30+ speakers with presentations, panels, fireside chats , Q&A and many more.
- Connect with industry leaders around the world: Without the constraints of geography, we’ll have thousands of industry leaders from across the globe coming together to collaborate.
- Complete virtual meetings platform: Send messages to connect 1-on-1 with your fellow attendees. Schedule meetings and use a virtual private meeting room to chat.
[Content provided by MarketsandMarkets]